The abstract is read at the publisher; the summary is JClub's.
B-cell–related pathways, including CD20-associated and immunoglobulin genes, are markedly upregulated in rheumatic mitral valve tissue, supporting B cells as a therapeutic target in RHD.
- Why it matters: RHD persists as a major cause of cardiovascular morbidity and mortality, but no treatment directly targets its autoimmune mechanisms.
- What they did: Transcriptomic profiling of rheumatic mitral valves using a 750 mRNA panel identified B-cell pathway upregulation, and a feasibility study in children with RHD in Dakar, Senegal tested rituximab.
- The result: In the RCT first-year preliminary safety analysis, children receiving rituximab showed decreased anti-streptolysin O titers and clinical improvement versus controls, suggesting anti-CD20 therapy may be disease-modifying.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.